US equities |
NVDA $239.69 ▲+0.33% MU $1,052.90 ▼-1.04% SPCX $172.48 ▲+0.81% MRVL $289.98 ▲+6.91% AMD $654.01 ▲+3.52% INTC $114.04 ▼-1.85% AVGO $377.00 ▲+4.00% TSLA $379.93 ▲+0.32%
FinancialContent

Anteris Technologies Global Corp. - Common Stock (NQ:AVR)

7.160 -0.390 (-5.17%)
Delayed Quote Updated: 3:22 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anteris Technologies Global Corp. - Common Stock

< Previous 1 2 Next >
News headline image
Anteris to Present at September Healthcare Investor Conferences
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces Results for the Second Quarter of 2026
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Results for the First Quarter of 2026
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Reports 2025 Financial Results and Provides Corporate Update
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
From Anteris Technologies Global Corp.
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
Why Did AVR Stock Surge Pre-Market Today? ↗
The company unveiled a $200 million dilution alongside a $90 million investment from healthcare technology heavyweight Medtronic. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Rebound, All Eyes On Trump’s Davos Speech: Why TSLA, NVDA, NFLX, AVR Are On Traders' Radar Today ↗
Retail sentiment on Stocktwits on SPY and QQQ turned ‘extremely bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
From Anteris Technologies Global Corp.
Via GlobeNewswire
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
From Anteris Technologies Global Corp.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Top movers in Thursday's after hours session ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Results for the Third Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
< Previous 1 2 Next >